Shandong Suncadia Medicine Co., Ltd.
suncadia.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
83
Active
42
Phase 3
13
Total enrollment
23,414
Pipeline matrix
Showing 40 of 65 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| HRS-7535 | — | — | — | 17 | |||
| HRS-1893 | — | — | — | 8 | |||
| HRS-2129 | — | — | — | 7 | |||
| HRS-8080 | — | — | — | 6 | |||
| HRS-1780 | — | — | — | 5 | |||
| Letrozole | — | — | — | — | 3 | ||
| HRS-7058 | — | — | — | — | 3 | ||
| Fulvestrant | — | — | — | — | 2 | ||
| HRS-1893 placebo | — | — | — | — | 2 | ||
| Anastrozole | — | — | — | — | — | 2 | |
| Exemestane | — | — | — | — | — | 2 | |
| Tramadol Hydrochloride SR | — | — | — | — | 2 | ||
| HRS-7535 Placebo | — | — | — | — | — | 2 | |
| HRS-1780 tablet placebo | — | — | — | — | — | 1 | |
| Fulzerasib | — | — | — | — | — | 1 | |
| Garsorasib | — | — | — | — | — | 1 | |
| Glecirasib Citrate | — | — | — | — | — | 1 | |
| HRS-8080 Tablet ; Dalpiciclib Isethionate | — | — | — | — | — | 1 | |
| Fulvestrant injection ;Dalpiciclib Isethionate | — | — | — | — | — | 1 | |
| Tamoxifen Citrate | — | — | — | — | — | 1 | |
| Blank Preparation. | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| HRS-1301 | — | — | — | — | 5 | ||
| HRS-2189 | — | — | — | — | 3 | ||
| HRS-6208 | — | — | — | — | 2 | ||
| HRS-6209 | — | — | — | — | — | 2 | |
| HRS-1358 | — | — | — | — | 2 | ||
| HRS-7085 | — | — | — | — | 2 | ||
| HRS-7535 tablet placebo | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy | — | — | — | — | — | 1 | |
| HRS-7058 + Cetuximab | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1826 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-1826 + SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-A1202 | — | — | — | — | — | 1 | |
| HRS-7058 + BP102 | — | — | — | — | — | 1 | |
| HRS-7058 + SHR-9839 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-A2102 +SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-9839(sc)+SHR-1316 | — | — | — | — | — | 1 | |
| HRS-7058 +SHR-1316 +BP102 | — | — | — | — | — | 1 |
25 more active programs hidden
Next readouts
- 2024-11-18
- 2025-05-30
- 2025-06
- 2025-08
- 2025-12
- 2026-05
- 2026-06
- 2026-06
- 2026-06
- 2026-07
Top conditions
- Type 2 Diabetes7
- Breast Cancer6
- Chronic Kidney Disease5
- Type 2 Diabetes Mellitus4
- Obstructive Hypertrophic Cardiomyopathy4
- Hyperlipidemia3
- Cardiomyopathy2
- Solid Tumors2
Frequently asked questions about Shandong Suncadia Medicine Co., Ltd.
- How many clinical trials does Shandong Suncadia Medicine Co., Ltd. have on ClinicalTrials.gov?
- Shandong Suncadia Medicine Co., Ltd. is listed as the lead sponsor on 83 clinical trials in ClinicalTrials.gov, 42 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shandong Suncadia Medicine Co., Ltd.'s trials are in Phase 3?
- 13 of Shandong Suncadia Medicine Co., Ltd.'s trials are in Phase 3, spread across 65 active drug programs.
- What therapeutic areas does Shandong Suncadia Medicine Co., Ltd. focus on?
- Shandong Suncadia Medicine Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Breast Cancer, Chronic Kidney Disease, Type 2 Diabetes Mellitus, Obstructive Hypertrophic Cardiomyopathy.
- When are Shandong Suncadia Medicine Co., Ltd.'s next clinical trial readouts?
- Shandong Suncadia Medicine Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy”, expected around 2024-11-18.